Maureen Riordan
Senior Deals Analyst
Latest From Maureen Riordan
Deals in Depth: June 2024
Four $1bn+ alliances were penned in June. In the top alliance by deal value, Ascidian Therapeutics signed an agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Roche received exclusive rights to Ascidian's RNA exon editing technology for undisclosed targets. Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, which will be responsible for certain preclinical activities, and further clinical development, manufacturing, and commercialization. Ascidian will receive an up-front payment of $42m as well as up to $1.8bn in research, clinical, and commercial milestone payments, as well as sales royalties.
Deals in Depth: May 2024
Six $1bn+ alliances were penned in May. In the top alliance by deal value, AC Immune SA granted Takeda an option to license exclusive global rights to active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will receive $100m up front and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1bn, plus sales royalties.
Deals in Depth: April 2024
Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.
Dealmaking Quarterly Statistics, Q1 2024
During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Deals in Depth: March 2024
Two $1bn+ alliances were penned in March. In the top alliance by deal value, Merus NV will use its Triclonics anitbody platform to discover new dual tumor-associated antigens targeting trispecific antibodies for Gilead Sciences. Merus will lead early-stage research activities for two programs, with an option to pursue a third. Gilead will have the right to license programs developed under the collaboration after the completion of select research activities. If Gilead exercises its option to license any such program from the collaboration, Gilead will be responsible for additional research, development and commercialization activities for such program. The deal could be worth up to $1.5bn for Merus.